Researchers examined the post-recurrence progression in patients with resected pancreatic ductal adenocarcinoma (PDAC) and the implications for treatment. Most PDAC patients experience recurrence within two years, with varying survival outcomes depending on the site of recurrence. Lung recurrence showed significantly longer post-recurrence survival. A subset of patients with local-only recurrence, especially those with specific markers for favorable tumor biology, had a chance for potential curative re-resections, highlighting the need for personalized treatment strategies in PDAC recurrence.
Journal Article by Rompen IF, Levine J (…) Javed AA et 11 al. in Ann Surg
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.